The psychedelic renaissance has reached its peak so far in 2026: over 380 clinical studies are running worldwide, three substances are approaching FDA approval, and Australia has published its first long-term data after three years of legal prescribing. Here is the current status — soberly contextualized, without hype.

Before we dive into individual studies, a look at the scope of the field as of Q1 2026:

The numbers speak for themselves: what was a fringe topic in psychiatry a decade ago is now one of the most dynamic research fields in neuroscience. Around 15 universities worldwide now have dedicated psychedelic research centers — including Johns Hopkins, Imperial College London, Charite Berlin, and the University of Zurich.

Status Quo

The most closely watched story in psychedelic research remains MDMA-assisted therapy for PTSD (post-traumatic stress disorder), driven by the Multidisciplinary Association for Psychedelic Studies (MAPS).

As a reminder: in August 2024, the FDA rejected the first approval application — not due to lack of efficacy, but over methodological concerns (unblinding, therapist effects, long-term safety). It was a shock for the community.

Since then, MAPS has responded:

• New Phase 3 study (MAPP3): Launched in March 2025, with improved design. 350 participants, stronger blinding (active placebo instead of inactive), standardized therapist protocol. First results expected Q4 2026.
• European study: The EMA (European Medicines Agency) has launched a parallel review process. A Europe-wide Phase 3 study with 12 sites has been running since September 2025.
• Realistic FDA timeline: Most optimistic estimate for US approval: end of 2027. Realistic: 2028.

What Does This Mean for Us?

The FDA decision on MDMA will set a precedent for all subsequent psychedelic substances — including LSD and psilocybin. Approval would legitimize the entire sector. Another rejection could set back the research boom by years.

[LINK: LSD and Neuroplasticity: How Psychedelic Substances May Reshape the Brain → /lsd-neuroplastizität/]

Compass Pathways, the highest-valued company in the psychedelic sector (market capitalization approx. 1.7 billion USD, as of Q1 2026), is conducting the largest psilocybin studies in history.

The COMP360 Study

• Indication: Treatment-Resistant Depression (TRD) — depression that does not respond to at least two antidepressants
• Design: Phase 3, randomized, double-blind, 22 sites in 10 countries
• Participants: 255 (Cohort 1 completed), 400+ (Cohort 2 ongoing)
• Cohort 1 result: COMP360 (25 mg synthetic psilocybin) showed a significant reduction in MADRS score (Montgomery-Asberg Depression Rating Scale) of 14.8 points vs. 9.4 points under placebo (p=0.003) after 6 weeks

The numbers sound encouraging, but there are limitations: the effect size is moderate (Cohen's d = 0.52), the unblinding rate was high (68% of participants could correctly guess whether they received psilocybin or placebo), and long-term data beyond 12 months are still pending.

Regulatory Outlook

Compass has received FDA Breakthrough Therapy Designation for psilocybin in TRD — this accelerates the review process but does not guarantee approval. An NDA (New Drug Application) could be filed in 2027, with possible approval in 2028–2029.

For us as the LSD derivatives community, the LSD-specific studies are naturally of particular relevance. Here are the most important ongoing programs:

Beckley Foundation / Maastricht University

The Beckley Foundation under Amanda Feilding has been a driving force in LSD research for decades. In collaboration with Maastricht University, two studies are currently running:

Study 1: LSD Microdosing for Attention Deficits

• 72 participants, double-blind, placebo-controlled
• Dose: 10 mcg and 20 mcg LSD tartrate vs. placebo
• Duration: 6 weeks (3x per week)
• Primary endpoint: cognitive performance (CANTAB battery)
• Status: data collection completed, publication expected Q3 2026

Study 2: LSD Microdosing and Creativity

• 48 participants, crossover design
• Investigating: divergent thinking, Remote Associates Test, insight problem-solving
• First results presented at ICPR 2025: significant effect on divergent thinking at 20 mcg, no significant effect at 10 mcg
• Full publication expected mid-2026

MindMed (Mind Medicine Inc.)

MindMed, one of the largest publicly traded psychedelic companies, is running several LSD programs:

MM-120: LSD for Generalized Anxiety Disorder (GAD)

• Phase 2b completed (2025): 198 participants
• Results: significant reduction in anxiety symptoms (HAM-A Score) at the 100 mcg dose vs. placebo after 12 weeks (p<0.001)
• Phase 3 launched Q1 2026: 360 participants, 20 sites
• This is currently the most advanced LSD therapy program worldwide

MM-120 Microdosing Study:

• Phase 2a, 60 participants, completed
• Investigating: ADHD symptoms under repeated LSD microdosing
• Results still under embargo, publication expected summer 2026

University of Basel / Liechti Lab

Matthias Liechti's lab at the University of Basel is a world leader in controlled human LSD research. Current projects:

• Pharmacological interaction study: How do SSRIs affect the effects of LSD? (Result: SSRIs dampen the subjective effects by approx. 40% — relevant for anyone taking antidepressants)
• Microdosing safety study: Long-term safety of 13 mcg LSD, 2x weekly over 8 weeks. No clinically relevant side effects detected, cardiological safety profile unremarkable (no significant 5-HT2B activation)
• LSD vs. psilocybin comparison study: Direct head-to-head comparison of both substances in 40 healthy subjects. Result: comparable subjective effects at equipotent doses, but different time profiles

[LINK: The 5-HT2A Serotonin Receptor: How LSD Works in the Brain → /serotonin-5ht2a-rezeptor/]

Since July 2023, specially approved psychiatrists in Australia can legally prescribe MDMA for PTSD and psilocybin for treatment-resistant depression. It was the first country in the world to take this step. After nearly three years, we now have initial data from real-world care:

The Numbers

• Approved psychiatrists: 87 (as of Q1 2026)
• Treated patients (psilocybin): approx. 1,400
• Treated patients (MDMA): approx. 600
• Cost per treatment: 15,000–25,000 AUD (approx. 9,000–15,000 EUR) — mostly not covered by health insurance
• Dropout rate: 8% (comparable to standard psychotherapy)

What the Data Show

The Australian TGA (Therapeutic Goods Administration) published a first report in February 2026:

• Psilocybin for TRD: 62% of patients showed clinically meaningful improvement after 12 weeks (defined as >50% reduction in PHQ-9 score). This is higher than in controlled studies — possibly due to selection bias (motivated patients who accept high costs).
• Safety: 14 serious adverse events reported, of which 3 psychiatric hospitalizations. No deaths. The serious event rate (0.7%) is below that of SSRIs in comparable populations.
• Challenges: High costs, limited availability of trained therapists, long waiting lists (average 4 months).

The FDA grants Breakthrough Therapy Designation (BTD) to substances that show "substantial improvement over existing therapies" in initial studies. This designation accelerates the approval process. Current status for psychedelic substances:

Five BTDs for psychedelic substances — this would have been unthinkable ten years ago. The fact that LSD received the BTD for anxiety disorders in 2024 is a historic milestone.

The big question occupying our community: what does clinical research have to do with the legally available derivatives (1BP-LSD, 1Fe-LSD)?

Direct Relevance

• All clinical LSD studies use LSD-25 (the original molecule), not the derivatives. The prodrug derivatives are metabolized in the body into LSD-25, and the effect at the receptor is identical.
• The safety data from clinical studies are therefore fundamentally transferable — with the caveat that the prodrug metabolization introduces its own variables.
• The dose equivalence is not 1:1 (150 mcg 1BP-LSD does not exactly equal 150 mcg LSD-25), which must be considered when applying study results.

Indirect Relevance

• Every positive clinical study legitimizes the exploration of psychedelic substances overall — including in non-clinical contexts.
• The growing evidence base increases political pressure for decriminalization or controlled legalization.
• The research provides our community with better data for informed decisions: safety profiles, interactions, optimal dosing protocols.

[LINK: How LSD Derivatives Work as Prodrugs in the Body → /was-ist-ein-prodrug/]

While LSD, psilocybin, and MDMA are still awaiting approvals, ketamine has long arrived in clinical practice. In the US, over 800 clinics now operate legal ketamine infusion therapies; in Germany, there are around 120 certified locations (as of Q1 2026).

The numbers from the US market are impressive: according to a Bain & Company analysis, revenue from ketamine therapies in 2025 was estimated at 3.2 billion USD — a growth of 58% compared to 2023.

However, criticism is growing:

• Quality control: Therapy standards vary widely between clinics. Some offer only infusions without accompanying psychotherapy.
• Long-term data: A meta-analysis in Lancet Psychiatry (January 2026) shows that the antidepressant effect wanes in 40% of patients after 3–6 months — repeated treatments are often necessary.
• Misuse potential: The FDA warned in December 2025 about the uncontrolled use of ketamine via telemedicine platforms.

Based on registered studies and announced milestones, here are the key expected events for the remainder of 2026 and early 2027:

Q2–Q3 2026:

• Beckley/Maastricht microdosing study: full results published
• MindMed microdosing study: results released
• Australia TGA: expanded annual report with 3-year data

Q4 2026:

• MAPS MAPP3: first interim analysis
• Compass COMP360 Cohort 2: results expected
• MindMed Phase 3 (LSD/GAD): first recruitment numbers

Q1 2027:

• Liechti Lab: LSD long-term safety data (12-month follow-up)
• Possible EMA position on MDMA

Is LSD already approved as a medication in 2026?

No. LSD is in Phase 3 studies for Generalized Anxiety Disorder (MindMed). FDA approval could come at the earliest in 2028–2029. Currently, LSD is not approved as a medication in any country — Australia allows the prescribing of psilocybin and MDMA, but not LSD.

Which psychedelic substance will be approved first?

Probably MDMA or psilocybin. MDMA for PTSD is furthest along in the approval process, followed by psilocybin for treatment-resistant depression. LSD for GAD is approximately 2–3 years behind.

What does the research mean for the legality of LSD derivatives?

Clinical research and the legality of research chemicals are different regulatory domains. However, positive clinical data increase the societal and political pressure to reconsider legislation. In the long term, clinical legitimization could pave the way for broader decriminalization.

2026 is a turning point for psychedelic research. The evidence base is becoming more robust, studies are getting larger and methodologically cleaner, and regulatory authorities are taking the field seriously. The question is no longer whether psychedelic substances will enter medicine, but when and how.

For us as a research community, this means: our observations and experiences are increasingly being validated by controlled studies. At the same time, the studies also reveal the limits — not everyone benefits, not every application is sensible, and the risks are real.

I update this article regularly as new study results are published. Bookmarking is worthwhile.

[LINK: LSD and Neuroplasticity: Current Research Findings → /lsd-neuroplastizität/] [LINK: LSD and Depression: Could Psychedelic Substances Help? → https://lsd-derivate.com/microdosing-angst-depression] [LINK: The History of LSD: From Hofmann to Today → /geschichte-lsd-derivate/]

Dr. Lena Voss holds a PhD in neuroscience and has been following the psychedelic research landscape since 2018. This article is regularly updated. Last update: April 2026. All information is based on peer-reviewed studies, ClinicalTrials.gov registrations, and official regulatory documents. Not medical advice.